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Abstract
The addition of rituximab to cyclophosphamide, vincristine and prednisolone (CVP) for advanced follicular lymphoma
increases median time to progression by 17 months. A US societal cost-effectiveness of R-CVP versus CVP is estimated for a
representative 50-year-old patient. Progression-free survival (PFS) and overall survival are based on a randomized Phase III
trial. Costs are estimated using Medicare reimbursement rates and published drug price data, and include drug and
administration costs, adverse events, treatment of relapses, and end-of-life care. Utility estimates are derived from the
literature and a 3% discount rate is employed. Mean overall survival is projected to be 1.51 years longer for patients assigned
to R-CVP versus CVP. The cost per quality-adjusted year of life gained is $28,565. The utility associated with stable or
progressive disease and the unit drug cost of rituximab most inﬂuence the ﬁndings. The cost-effectiveness ratio of R-CVP
compared with CVP is projected to be cost-effective in the United States under a range of sensitivity analyses.
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Introduction
Approximately 22% of the more than 55,000 patients
diagnosed this year in the United States with non-
Hodgkin lymphoma (NHL) are classiﬁed as follicular
[1]. The disease course of follicular lymphomas is
considered slowly progressive, involving repeated
relapses and a median survival of 6–11 years
depending on the stage of disease [1–6].
Initial treatment of follicular lymphoma with
chemotherapy can often achieve a response, but
almost all patients relapse within 4–5 years.
Although there is no consensus on ﬁrst-line therapy
of follicular lymphoma, single agents such as
chlorambucil or combination regimens such as
cyclophosphamide, vincristine and prednisolone
(CVP) or cyclophosphamide, doxorubicin, vincris-
tine and prednisolone (CHOP) are commonly used
treatment regimens.
Rituximab (Rituxan
1, Genentech, Inc., South San
Francisco, CA) is a genetically engineered chimeric
murine/human monoclonal antibody directed against
the CD20 antigen found on the surface of normal
and malignant B lymphocytes. The antibody is an
IgG1 kappa immunoglobulin containing murine
light- and heavy-chain variable region sequences
and human constant region sequences. Rituximab
was found to cause lysis of CD20þ lymphoma cells
via complement-mediated cytotoxicity, antibody-
dependent cellular cytotoxicity and, directly, by
causing apoptosis. Rituximab has demonstrated
single-agent activity in the treatment of patients
with relapsed or refractory low-grade or follicular,
CD20þ B-cell NHL [7], which led to the initial
approval for this indication in 1997. In a Phase III
clinical trial, Marcus et al. studied the addition of
rituximab to the widely used combination regimen of
CVP [8]. The trial demonstrated that rituximab used
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CVP, increased overall and complete rates response
(overall: 81% versus 41%; complete: 57% versus
10%; p50.001) [8]. Importantly, R-CVP also
signiﬁcantly prolongs median time to progression
from 15 to 32 months (p50.0001). This trial
formed the basis for the FDA approval in September
2006 of the expanded use of rituximab in combina-
tion with CVP for patients with previously untreated
CD20þ, B-cell, follicular NHL.
The objective of this study is to determine whether
R-CVP is a cost-effective alternative to CVP for ﬁrst-
line treatment of advanced follicular lymphoma. The
factors that inﬂuence the cost-effectiveness of R-CVP
also are examined.
Materials and methods
Analytical framework
The principles of decision-theoretical modeling
commonly applied in health economic appraisals
are used in this analysis. The model framework is
based on the Markov model, which provides a
convenient way of modeling disease progression
that monitors events occurring in a hypothetical
cohort of patients under various scenarios. Key
parameters of the model are based on balanced
summary of clinical evidence and reasonable as-
sumptions. In a Markov model, the patient may be in
one of a ﬁnite number of states of health and events
of interest are modeled as transitions from one state
to another. For each state, analysts assign a utility
used as an adjustment factor for quality of life. Utility
weights typically range from 0 to 1, where 0
represents death, 1 represents perfect health; the
values between 0 and 1 represent degrees between
these extremes. The contribution to total utility,
commonly referred to as quality-adjusted life years
(QALYs), of a particular state depends on the length
of time spent in a state multiplied by the utility of that
state. The model includes 3 states: (1) time until
progression or death, referred to as progression-free
survival (PFS), (2) time after progression and (3)
death.
Target population
The model includes the costs and effects of R-CVP
treatment compared with CVP in a representative
patient with advanced follicular lymphoma. The
target population consists of patients age 18 years
and older with Ann Arbor Stage III or IV follicular
NHL with International Working Formulation
(IWF) categories B, C, or D (WHO follicular grades
1–3), who have Eastern Cooperative Oncology
Group (ECOG) performance score between 0 and
2, and have untreated and measurable disease.
Among all enrolled patients in the pivotal trial,
median age was 53 years, 70% had Ann Arbor Stage
IV disease, 4.4% had hemoglobin level 5100 g/L,
26% had serum LDH4upper limit of normal, 64%
had bone marrow involvement and 32% had 43
nodal sites with diameters greater than 3 cm. The
Follicular Lymphoma International Prognostic
Index (FLIPI) score was greater than 2 in 53% of
patients [8].
Interventions
A cycle of CVP consists of cyclophosphamide
750 mg/m
2 IV Day 1, vincristine 1.4 mg/m
2 up to
2 mg/m
2 IV Day 1, and prednisolone 40 mg/m
2
orally Days 1–5 of each cycle. R-CVP consists of
CVP plus rituximab 375 mg/m
2 given on the ﬁrst day
of each cycle. CVP þ/7 R cycles are repeated every
21 days for up to 8 total cycles (Figure 1). Patients
who did not achieve a partial response after 4 cycles
of therapy were removed from the trial. If a
rituximab-induced infusion reaction occurs, therapy
is interrupted and all symptoms must resolve before
rituximab is continued, or CVP restarted. Dosages of
cytotoxic drugs were reduced if grades 2/4 neurolo-
gical or grade 3/4 hematological toxicity occurred.
Progression-free survival and overall survival
Progression-free survival (PFS) and overall survival
for the ﬁrst 4 years after initiating treatment are based
on Kaplan–Meier survival analyses of a pivotal
clinical trial (Figure 2) [8]. PFS and overall survival
are extrapolated beyond the trial’s 4 years of follow-
up based on published ﬁndings of long-term ob-
servational studies. For example, Solal-Celigny et al.
reported the prognosis of 4167 patients with folli-
cular lymphoma diagnosed between 1985 and 1992
[5]. Applying an annual mortality risk of 6.9%
approximately replicates the overall survival reported
in this and related studies [3–6].
Costs
The costs in these models are obtained from the
initial regimen of chemotherapy administered to all
the patients. Unit drug costs are derived from
Medicare J-codes (CMS-approved reimbursement
rates) [9]. The CVP regimen requires 5 doses of
40 mg/m
2 of prednisolone per cycle. For the
average adult, this requires a net dose of 1.72 m
26
100 mg/m
265¼860 mg. At a cost of less than
$0.01/mg, the cost of prednisolone in one cycle of
CVP is $5. Table I shows the calculation of the costs
228 J. Hornberger et al.of CVP. The actual dose given is calculated from the
normalized dose and a standard BSA (1.72 m
2). The
recommended does is calculated from the product
insert recommendations. The actual dose divided by
the recommended dose equals the percent of the
recommended administered. The cost per cycle is
the cost of one cycle of the recommended dose,
calculated using Mosby 2006 drug costs. Finally, the
Figure 1. First-line R-CVP First R versus CVP.
Figure 2. (a) Observed survival based on the trial data and then predicted using hazard ratios. (b) Observed progression-free survival and then
predicted using hazard ratios.
Table I. Calculation of costs of CVP.
CVP R-CVP
CTX Vincristine Prednisolone CTX Vincristine Prednisolone
Normalized dose given (divided by BSA) 4866 7.1 1323 5315 7.7 1471
Recommended dose 10,320 19.3 6880 10,320 19.3 6880
Actual dose given 8370 12.2 2276 9142 13.2 2530
Percent 81.1% 63.4% 82.7% 88.6% 68.8% 36.8%
Cost per cycle $47.40 $13.37 $13.32 $46.60 $13.37 $13.32
Cost per course $302.35 $67.81 $88.11 $330.25 $67.81 $88.11
$458.27 $501.76
CTX, cyclophosphamide; BSA, body surface area.
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cycle, the number of cycles per course and the
percent administered. The same cost for CVP is used
in both arms. Rituximab is sold as 10 mL (100 mg)
and 50 mL (500 mg) vials, with equal unit cost
regardless of vial size ($5.28/mg). Rituximab is
assumed to be purchased in 100 mg increments
and excess drug per vial would be wasted. The dose
is multiplied by the cost per mg to give the cost per
cycle. The cost per course equals the product of this
cost per mg and the number of cycles per course
(Table II).
Administration costs are calculated by multiplying
the required number of hours of infusions by the cost
per hour listed for the appropriate current procedural
terminology (CPT) codes [9]. The number of hours
required to receive rituximab are based on the
administration section and toxicity proﬁle of ritux-
imab monotherapy reported in the product insert.
For the R-CVP arm, both rituximab and CVP are
administered together, whenever possible, to mini-
mize costs. Rituximab takes the longest time to infuse
and thus drives the administration costs. Based on
data from the product insert and a clinical expert
(NV), the average time required for the ﬁrst
administration is assumed to be 5.4 h, and 4.4 h
for subsequent administration. This takes into
account the estimate from clinical experts regarding
the proportion of patients who develop mild and
severe infusion reaction (approximately 77% of
patients in the ﬁrst administration experience an
infusion reaction, requiring the slowing of adminis-
tration). Table III shows the cost calculation for the
R-CVP arm for the ﬁrst cycle, and subsequent cycles.
The CVP arm is simpler requiring only 2 costs: the
initial administration plus one additional infusion
(prednisolone is administered orally and thus does
not incur administration costs).
The known safety proﬁle of rituximab monother-
apy includes infusion reactions consisting of fever,
chills/rigors, nausea, angioedema, asthenia and head-
ache. Based on the product insert, symptoms were
found to be most common with the ﬁrst rituximab
monotherapy infusion (77%), decreasing in inci-
dence to 30% with the fourth infusion, and 14% with
the eighth infusion [10]. An infusion reaction is
assumed to prolong administration times, thereby
increasing the costs of administration. Only Grade 3
and 4 adverse events with at least 2% rate difference
between the two arms of the trial are considered as
contributing substantially to medical costs. The costs
of treatment of adverse events are multiplied by the
probability of occurrence reported in the trial. Both
fatigue and granulocytopenia occur in higher fre-
quencies in the R-CVP arm. Two options were
available for the treatment of granulocytopenia,
ﬁlgastrim, or pegﬁlgastrim. Filgastrim results in
higher costs; hence, it is used so as to bias the
analysis against R-CVP. The costs of fatigue are
estimated from the cost of an ofﬁce visit that would
result from the condition.
The cost of subsequent treatment regimen is
calculated from the average price of the most
common regimens recommended by the National
Comprehensive Cancer Network (NCCN) for NHL
(aside from those including rituximab) [11]. Ritux-
imab monotherapy is also indicated for relapsed/
refractory follicular lymphoma. The following treat-
ment regimens are considered: chlorambucil, cyclo-
phosphamide, CHOP, ﬂudarabine, FMD
(ﬂudarabine, mitoxantrone, dexamethasone), ritux-
imab monotherapy, R-CHOP, R-ﬂudarabine and
R-FMD. Moreover, based on preliminary trial
evidence [12–14], some physicians are offering
rituximab after initial therapy in patients who have
achieved a complete or partial response. We there-
fore include costs associated with such regimens in
the model, assuming that 70% of patients would
receive at least one additional course of rituximab
(7 cycles on average).
The subsequent treatment would have no addi-
tional effect on OS on either arm and would add a
measure of disutility as well to the six-month cycle in
which it was applied. The model applies one round of
subsequent treatment at the median time to progres-
sion and one year thereafter for each arm. Based on
Table II. Rituximab cost calculation.
Dosing information Estimate
Intended number of cycles 8
Mean body surface area (m
2) 1.72
Prescribed dose (mg per m
2) 375
Dose per cycle (mg) 645
Dose purchased (mg)* 700
Cost per cycle $3372
Percent of dose given 89.1%
Cost per course $24,034
*One 500 mg vial (50 mL) and two 50 mg vials (10 mL).
Table III. R-CVP arm administration costs.
Administration costs CPT Code Fee Amount
First cycle
Initial administration cost 96413 $172.81 1
Additional hour cost 96415 $39.03 4.4
Additional infusion cost 96417 $84.51 2
Total Cost $513.56
Subsequent
Initial administration cost 96413 $172.81 1
Additional hour cost 96415 $39.03 3.4
Additional infusion cost 96417 $84.51 2
Total Cost $474.53
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be available to relapsed patients and that these
regimens were tried in equal proportions. The
average costs for drugs and administration are
included to account for one round of salvage therapy.
Table IV shows the six different regimens, their cost
and the average cost of salvage therapy.
The prospect that some patients may undergo
stem-cell transplantation (SCT) is included in the
model. A comprehensive search of PubMED failed
to identify relevant papers regarding the proportion
of patients with advanced follicular NHL who
undergo SCT as part of their subsequent therapy.
Based on a limited survey of NHL experts’ opinions,
an estimate of 10% was used for patients that
undergo SCT based on those who are alive by year
7. The cost of this procedure is derived from a review
of costs [15] and the average of the costs of SCT
procedures performed for NHL patients was se-
lected. The1992 cost was updated by applying an
inﬂation factor to update the mean cost to 2006
dollars.
Costs of end-of-life care also are included in the
analysis. Hoover et al. stated that the costs of health
care increase signiﬁcantly in the last year of life [16].
More speciﬁcally, they calculate the cost of the
terminal year of life, based on data from the
Medicare Current Beneﬁciary Survey.
The analysis includes the costs of adverse events.
Only Grade 3 and 4 events are considered, and only
if the difference in prevalence between the two arms
reported in the trial exceeded 2%. The costs are
calculated by multiplying the incidence by the unit
costs of treatment.
Utilities
Cost-effectiveness models calculate the incremental
cost of a given technology per beneﬁt gained.
Though many measures of beneﬁts exist, the
QALY has been widely adopted as a standard
measure in cost-effectiveness research. Because
chemotherapy causes a signiﬁcant decrease in quality
of life, its positive effects (such as gain in overall
survival) are partially negated by its toll on quality of
life at the time of administration.
The model incorporates the effects of QOL in
different scenarios by assigning utility weights for
follicular lymphoma [17] and ‘‘disutility’’ tariffs to
certain scenarios, such as chemotherapy, SCT and
end-of-life care [18]. This accounts for a day with
chemotherapy holding less value than a day in perfect
health. Through sensitivity analyses, a wide range of
utility values are explored to determine their effect on
the outputs of the model.
Other assumptions
To account for the changing value of money over
time, two time-discount parameters are included in
the model. The ﬁrst is the societal time-discount rate,
a correction for costs and beneﬁts incurred at future
dates. Because a dollar or beneﬁt incurred today
typically is considered preferable to a dollar or beneﬁt
incurred later, the model applies a standard time-
discount rate to all costs and beneﬁts incurred in
future years [19]. The medical consumer price index
is a parameter published by the Bureau of Labor
Statistics, which adapts prices to reﬂect currents
trends in the rising prices of healthcare [20]. This
term inﬂates health care costs incurred in future
years.
The time horizon is set to 30 years, which in this
population, approximates a lifetime model. The
ramiﬁcations of choosing different time horizons
are explored. Table V summarizes all the variables
discussed and the evidence sources.
Quality of evidence
Evidence was sought from the best available sources,
including the randomized trial itself, based on
systematic searches of the literature using PubMed
and SciSearch. In instances where no published data
was available, evidence was based on expert opinion.
The quality of the evidence is graded based on study
design, results and limitations, using two grading
systems [21,22]. The ﬁrst system assesses evidence
pertaining to inference about treatment effects. The
grading system assumes that ﬁndings from a well-
controlled randomized clinical trial represent Level A
evidence, whereas ﬁndings from an observational
study represent level B evidence. Level C evidence
derives from other sources, such as expert opinion or
small case series. The grading level is altered by one
or two levels based additional criteria, such as
strength of association, consistency of ﬁndings, level
of potential reporting bias, concerns about study
limitations and generalizability of the ﬁndings.
Table IV. Salvage therapy regimens and costs over 6 months.
Regimen Utilization (%) Cost
Chlorambucil 6 $935
Cyclophosphamide 6 $1541
CHOP 6 $3829
Fludarabine 6 $9001
FMD 6 $22,084
Rituximab-containing regimens* 70 $29,084
Average $23,206
*Includes R-CHOP, R-CVP, R-COP, R-F, R-FMD, with patients
receiving at seven cycles of rituximab.
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represents data obtained from the stakeholder. For
example, if the analysis is done from the perspective
of the Centers for Medicare and Medicaid services
(CMS), Level A evidence would be based on CMS
claims analyses. Another example is obtaining
evidence from an utility assessment project where
the participants are a random sample from the stake-
holder’s stated constituency. Level B evidence in-
volves obtaining estimates that pertain to the
stakeholder perspective, but was not directly ana-
lyzed for this project (e.g., from a review of the
literature). Level C evidence represents data ob-
tained from other database sources, such as utility or
cost registries. Level D evidence represents data from
other sources, such as Delphi panel of experts. The
grading level can be altered to reﬂect strengths and
limitations of the study. It is worth noting that utility
or cost data from a randomized control trial may be
graded from A to C, depending on the particular
relevance of the information to the stakeholder. For
example, cost data analyzed in a trial in which most
of the participants were from a country or healthcare
system substantially different from that of the stake-
holder has lower relevance, and so may be assigned
to Level C evidence. Figure 3 shows the criteria used
to grade the data on treatment effects and the cost
and utility data. Table V shows the grades for all the
data and their sources that are used in the present
analyses.
Results
R-CVP is projected to increase mean PFS by 1.93
years compared with CVP alone. R-CVP increases
mean overall survival by 1.51 years and QALYs by
0.93 years (Table VI).
Drugs, administration and follow-up tests and
visits incur the highest added costs associated with
adding rituximab to CVP. The total cost difference
between the two arms for the trial was $26,439.
Treatment with rituximab incurs additional costs in
all categories, except for salvage treatment.
The cost of rituximab alone comprises 92% of the
total cost difference between the regimens. All other
cost categories had far less impact on total cost and
this is conﬁrmed in sensitivity analyses. It is
important to note that while salvage therapy, end-
of-life care and post-treatment follow up incur costs
above $20,000, the difference in these costs between
the two treatment arms is minimal and thus does not
signiﬁcantly affect the results.
Administration costs varied between R-CVP
and CVP because of the longer time required to
Table V. Summary of base-case estimates, ranges for sensitivity analyses and quality of the evidence.
Parameter
Base-case estimate
Range for
sensitivity analyses
Quality of
evidence R-CVP CVP
Utilities
Follicular lymphoma pre-progression 0.805 0.70 to 90 B
Post-progression 0.618 0.52 to 0.72 B
Tariffs
Chemotherapy 70.15 70.3 to 0 C
Stem cell transplantation 70.20 70.4 to 0 C
End-of life (last 6 months) 70.30 70.6 to 0 C
Costs
Chemotherapy drugs
Rituximab $24,034 – +25% A
CVP $502 $458 +25% A
Chemotherapy administration $3,529 $1,702 +25% A
Adverse events $580 $95 +25% A
After treatment
Follow-up tests and visits Approximately $142
every 3 months
+25% B
Follow-up treatment $23,206 725% to þ100% B
Stem cell transplantation $75,352 +25% B
End-of-life care $21,463 +25% B
Other variables
Societal time discount rate 3% 0%–5% A
Time horizon Lifetime 5 years to lifetime B
CVP, chemotherapy regimen containing cyclophosphamide; vincristine and prednisolone.
See Figure 3 for grading system.
Cost of laboratories per month; increase by $841 for periodic CT scans in ﬁrst 2 years.
232 J. Hornberger et al.administer rituximab. The addition of rituximab to
the CVP regimen results in a higher incidence of
adverse events, thereby increasing those costs. High-
er follow up costs were mainly due to years of life
gained, resulting in more follow-up care. Increased
survival also increases the costs due to SCT because
more patients are alive after 7 years to undergo the
procedure. The trial data showed a cost-effectiveness
ratio of $28,565 per quality-adjusted life-year gained.
Sensitivity analyses
Figure 4 shows the effects of changing the value of
the inputs on the outcome of the model. The utility
of follicular lymphoma and the cost for a course of
rituximab are shown to most inﬂuence the cost per
QALY gained. Lower utility associated with follicular
lymphoma is associated with higher cost-effective-
ness ratio. The cost of rituximab also contributes
signiﬁcantly to the model outcomes. Changing the
cost for a course of rituximab by +25% varies
the cost-effectiveness ratio by $12,983. In none of
the sensitivity analyses did the cost-effectiveness of
R-CVP versus CVP exceed $50,000 per QALY
gained.
Discussion
Therapeutic options for patients with follicular
lymphoma are extensive, ranging from single-agent
chemotherapy to combination chemotherapy regi-
mens. Patients typically achieve high complete
response rates (*60%) with frontline therapy, with
remission durations of up to 3 years [3,23].
Eventually, patients experience relapse and are
treated with a series of chemotherapeutic regimens
over their lifetime, with diminishing efﬁcacy.
Figure 3. Quality of the evidence – grading system.
Table VI. Base-case results.
Endpoint R-CVP CVP Difference
OS (yr) 13.68 12.17 1.51
PFS (yr) 3.78 1.84 1.93
QALY
Remission 6.40 5.51 0.89
Chemotherapy 70.15 70.15 0.00
Salvage treatment 70.19 70.22 0.03
End of life 70.21 70.22 0.01
Total 5.85 4.93 0.93
Costs
Chemotherapy drugs $24,536 $458 $24,078
Chemotherapy
administration
$3529 $1702 $1827
Adverse events $580 $95 $485
Follow-up tests and visits $13,348 $12,051 $1297
Stem cell transplantation $5123 $4514 $609
Salvage treatment $34,466 $36,610 7$2144
End of life $24,025 $23,737 $287
Total $105,607 $79,168 $26,439
Cost per life-year gained $17,504
Cost per QALY gained $28,565
OS, overall survival; PFS, progression-free survival; QALY,
quality-adjusted life years; CVP, chemotherapy regimen containing
cyclophosphamide, vincristine and prednisolone.
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to assess the clinical outcome and patient beneﬁt
of the addition of rituximab to CVP chemotherapy
in frontline treatment [8]. The trial showed that
rituximab added to a CVP regimen signiﬁcantly
increased PFS. Although overall survival was not a
primary endpoint of the trial (that is, the trial was not
powered to show statistical signiﬁcance by 4 years),
the difference in survival in the two arms was 8%
apart at 4 years, showing no trend towards conver-
gence thereafter. R-CVP, therefore, is projected to
increase overall lifetime costs for frontline treatment
of advanced follicular lymphoma; however, the cost-
effectiveness ratio of R-CVP versus CVP is less than
$30,000 per QALY gained.
Sensitivity analyses show that the cost for adding
rituximab to CVP and the utility associated with
follicular lymphoma were the variables that most
inﬂuenced cost-effectiveness. Because both treat-
ment arms incur the CVP drug costs, increasing or
decreasing these costs has minimal effect on the cost-
effectiveness. It is important to note that many of the
costly categories (e.g., salvage therapy) have little
effect in this model because over a patient’s lifetime
with follicular lymphoma, few patients will incur
these costs. The inﬂuential variables, therefore, are
not necessarily the absolute costs of each procedure,
but the total difference in costs between each arm.
The direct costs of the two arms differ mainly
because of the additional cost of rituximab. The
beneﬁts gained from the added drug stem from
increased efﬁciency in the form of delayed relapse.
Other regimens are also used for ﬁrst-line treat-
ment of follicular NHL. In this study, we focused on
the cost-effectiveness of rituximab used in combina-
tion with CVP. Our approach, however, could
provide a basic framework for cost-effectiveness
analyses of other induction regimens where evidence
of patient beneﬁt is demonstrated in randomized
Phase III studies, such as trials of R-CHOP versus
CHOP [24], R-CHVP versus CHVP [25], R-MCP
versus MCP [26] and R-FCM versus FCM [12,27].
The sensitivity analyses show that the cost of
Rituximab is among the most important factors
inﬂuencing cost-effectiveness, especially compared
with the other components of the chemotherapy
regimen. All regimens mentioned above use less or
the same number of cycles as used in the current
study; hence, the additional costs of chemotherapy is
unlikely to be higher than reported here. Addition-
ally, Schulz et al. [28] reported a detailed meta-
analysis of rituximab combination therapies, showing
Figure 4. Sensitivity analyses.
234 J. Hornberger et al.lower hazard ratios (0.42–0.60) for overall survival
than reported by Marcus et al. (0.70) [28] A formal
analysis of these other regimens therefore would
likely demonstrate cost-effectiveness ratios that are
even lower than what we found with R-CVP
compared with CVP.
The cost-effectiveness of rituximab for ﬁrst-line
follicular lymphoma has yet to be formally assessed in
other countries. The sensitivity analyses show that
cost of Rituximab is one of the key inﬂuencers of the
cost-effectiveness ratio. In many countries, rituximab
is reimbursed at a lower level – adjusted for currency
exchange rates – than in the United States. Hence,
rituximab may be found to be more cost-effective
outside of the United States. For other indications,
such as diffuse large B-cell lymphoma, European
health technology groups have concluded that a
rituximab-based regimen, R-CHOP, is cost-effective
and, as such, rituximab has been reimbursed for this
indication. The extent to which health technology
groups conclude that rituximab provides sufﬁcient
value for money for ﬁrst-line follicular lymphoma
also depends on the stakeholder’s willingness to
reimburse for health technologies; in other
words, the country’s threshold of acceptable cost-
effectiveness.
These analyses should be interpreted in light of the
study’s potential limitations. First, clinical trial data
was only available up to 4 years, whereas patients
with follicular lymphoma are reported to have a
median survival of 6 to 11 years [1–6]. To capture
the implications of frontline chemotherapy with or
without rituximab, survival is estimated after 4 years
based on hazard ratios reported in the literature.
Experience in other economic analyses of oncology
interventions reveals that some clinicians are am-
bivalent about using non-trial data to estimate
treatment effects beyond the duration of the trial.
However, technology assessment guidelines (e.g.,
ISPOR or US Public Health) recommend estimating
the potential treatment effect over the potential
duration of the illness. To reconcile these different
perspectives, the time horizon was selected that
encompasses the patient’s entire lifetime, but the
duration of treatment effect was varied from 5 years
to a lifetime. Even when setting the treatment effect
to only 5 years, the cost-effectiveness ratio increases
only slightly from $28,565 to $34,128. The extra-
polations have minimal effect on the cost-effective-
ness of R-CVP.
Besides the duration of treatment effect, the
second most inﬂuential variable is the cost of
rituximab. The cost-effectiveness ratio is composed
of two parts: the additional price of the new
technology in the numerator and its added beneﬁt
in the denominator. In practice, the cost of a
technology and its effect on overall survival can often
approximate the outcome of the all-inclusive model.
Therefore, it is unsurprising that altering the cost
would have a large effect on the results. The cost of
rituximab alone does in fact inﬂuence the cost-
effectiveness.
Based on published BLS data, the rate of medical
inﬂation is higher than the discount rate [20]. This
has the effect of making future costs more expensive
than present costs. As with all the inputs, the
ramiﬁcations of this assumption were explored with
sensitivity analyses. The societal time discount rate is
among the top ﬁve sensitive inputs in the model. A
discount rate of 3% has been widely accepted [19],
and choosing a value less than the medical inﬂation
rate biases the model against R-CVP, because the
regimen causes other costs to be delayed, which in
turn increases them as result of the inﬂation factor.
The present analysis is consistent with previously
reported cost-effectiveness analyses of rituximab for
other NHL indications. In diffuse large B-cell
lymphoma, R-CHOP is cost-effective relative to
CHOP at less than $20,000 per QALY gain [29–
31]. Rituximab monotherapy also has been reported
to be cost-effective compared with observation only
from a Canadian healthcare perspective in the
maintenance treatment of relapsed/refractory follicu-
lar lymphoma [32].
In summary, ﬁrst-line treatment of R-CVP com-
pared with CVP alone is likely to result in a cost
effectiveness ratio of approximately $30,000 per
QALY gained. Cost-effectiveness ratios less than
$100,000 per QALY gained are typically considered
affordable in the US oncology marketplace [33].
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